Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Toppari, Jorma


IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

Online
ISSN
2191-0251
See all formats and pricing
More options …
Volume 29, Issue 7

Issues

Central diabetes insipidus as a very late relapse limited to the pituitary stalk in Langerhans cell histiocytosis

Shunsuke Nakagawa
  • Corresponding author
  • Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City 890-8520, Japan, Phone: +81-99-275-5354, Fax: +81-99-265-7196
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Yuichi Shinkoda / Daisuke Hazeki / Mari Imamura / Yasuhiro Okamoto
  • Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Kiyoshi Kawakami / Yoshifumi Kawano
  • Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-04-18 | DOI: https://doi.org/10.1515/jpem-2015-0391

Abstract

Central diabetes insipidus (CDI) and relapse are frequently seen in multifocal Langerhans cell histiocytosis (LCH). We present two females with multifocal LCH who developed CDI 9 and 5 years after the initial diagnosis, respectively, as a relapse limited to the pituitary stalk. Combination chemotherapy with cytarabine reduced the mass in the pituitary stalk. Although CDI did not improve, there has been no anterior pituitary hormone deficiency (APHD), neurodegenerative disease in the central nervous system (ND-CNS) or additional relapse for 2 years after therapy. It was difficult to predict the development of CDI in these cases. CDI might develop very late in patients with multifocal LCH, and therefore strict follow-up is necessary, especially with regard to symptoms of CDI such as polydipsia and polyuria. For new-onset CDI with LCH, chemotherapy with cytarabine might be useful for preventing APHD and ND-CNS.

Keywords: diabetes insipidus; Langerhans cell histiocytosis; relapse; pituitary stalk

References

  • 1.

    Berres ML, Lim KP, Peters T, Price J, Takizawa H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014;211:669–83.Web of ScienceGoogle Scholar

  • 2.

    Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, et al. Improved outcome in the treatment of pediatric multifocal langerhans cell histiocytosis. Results from the Japan Langerhans Cell Histiocytosis Study Group-96 Protocol Study. Cancer 2006;107:613–9.Google Scholar

  • 3.

    Arceci RJ. Histiocytosis syndromes. In: Lanzkowsky P, ed. Manual of pediatric hematology and oncology, 5th ed. London, UK: Elsevier; 2011:567–98.Google Scholar

  • 4.

    Broadbent V, Pritchard J. Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible? Med Pediatr Oncol 1997;28:289–93.Google Scholar

  • 5.

    Dunger DB, Broadbent V, Yeoman E, Seckl JR, Lightman SL, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med 1989;321:1157–62.Google Scholar

  • 6.

    Minkov M, Steiner M, Pötschger U, Aricò M, Braier J, et al. Reactivations in multisystem Langerhans cell histiocytosis: Data of the International LCH Registry. J Pediatr 2008;153:700–5.Web of ScienceGoogle Scholar

  • 7.

    Imashuku S, Kinugawa N, Matsuzaki A, Kitoh T, Ohki K, et al. Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems. Int J Haematol 2009;90:506–12.Google Scholar

  • 8.

    Grois N, Pötschger U, Prosch H, Minkov M, Arico M, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006;46:228–33.Google Scholar

  • 9.

    Rosenzweig KE, Arceci RJ, Tarbell NJ. Diabetes insipidus secondary to Langerhans’ cell histiocytosis: is radiation therapy indicated? Med Pediatr Oncol 1997;29:36–40.Google Scholar

  • 10.

    Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010;156:873–81.Google Scholar

  • 11.

    Shioda Y, Adachi S, Imasuku S, Kudo K, Imamura T, et al. Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan. Int J Hematol 2011;94:545–51.Google Scholar

  • 12.

    Dhall G, Finlay JL, Dunkel IJ, Kellie SJ, Allen JC, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer 2008;50:72–9.Web of ScienceGoogle Scholar

  • 13.

    Imashuku S, Shioda Y, Tsunematsu Y, Imamura T, Morimoto A, et al. VCR/AraC chemotherapy and ND-CNS-LCH. Pediatr Blood Cancer 2010;55:215–6.Google Scholar

About the article

Received: 2015-09-29

Accepted: 2016-03-07

Published Online: 2016-04-18

Published in Print: 2016-07-01


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 29, Issue 7, Pages 873–878, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2015-0391.

Export Citation

©2016 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Cheng Qin, Jiaheng Li, and Ke Tang
Endocrinology, 2018, Volume 159, Number 9, Page 3458
[2]
Zhen Huo, Tao Lu, Zhiyong Liang, Fan Ping, Jie Shen, Jingjing Lu, Wenbing Ma, Dachun Zhao, and Dingrong Zhong
Diagnostic Pathology, 2016, Volume 11, Number 1

Comments (0)

Please log in or register to comment.
Log in